Separation and quantification of Azvudine in plasma of patients with COVID-19 using LC-MS/MS-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Separation and quantification of Azvudine in plasma of patients with COVID-19 using LC-MS/MS

Published:2023-11 Issue: Volume:236 Page:115736
ISSN:0731-7085
Container-title:Journal of Pharmaceutical and Biomedical Analysis
language:en
Short-container-title:Journal of Pharmaceutical and Biomedical Analysis

Author:

Liu Zhijun,Liang Fengying,Gao Shouhong,Zhu Xiujing,Song Xinhua,Chen Wansheng^ORCID,Tao Xia,Wang Zhipeng,Xu Deduo

Publisher

Elsevier BV

Subject

Clinical Biochemistry,Spectroscopy,Drug Discovery,Pharmaceutical Science,Analytical Chemistry

Reference18 articles.

1. WHO Tracking SARS-CoV-2 variants. 〈https://www.who.int/activities/tracking-SARS-CoV-2-variants〉 Date accessed:December 29, 2022 Google Scholar.

2. Characterisation of SARS-CoV-2 variants in Beijing during 2022: an epidemiological and phylogenetic analysis;Pan;Lancet,2023

3. W.H.O. Coronavirus (COVID-19) Dashboard | WHO Coronavirus (COVID-19) Dashboard With Vaccination Data. 〈https://www.who.int/〉.

4. Azvudine, a novel nucleoside reverse transcriptase inhibitor showed good drug combination features and better inhibition on drug-resistant strains than lamivudine in vitro;Wang;PLoS One.,2014

5. The first Chinese oral anti-COVID-19 drug Azvudine launched;Yu;Innov. (Camb. ),2022

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP